Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The Y2 receptor agonist PYY(3-36) increases the behavioural response to novelty and acute dopaminergic drug challenge in mice.

Stadlbauer U, Weber E, Langhans W, Meyer U.

Int J Neuropsychopharmacol. 2014 Mar;17(3):407-19. doi: 10.1017/S1461145713001223. Epub 2013 Oct 17.

PMID:
24131590
2.

Dopaminergic transplants normalize amphetamine- and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum.

Cenci MA, Kalén P, Mandel RJ, Wictorin K, Björklund A.

Neuroscience. 1992;46(4):943-57.

PMID:
1347413
3.
5.

Administration of the Y2 receptor agonist PYY3-36 in mice induces multiple behavioral changes relevant to schizophrenia.

Stadlbauer U, Langhans W, Meyer U.

Neuropsychopharmacology. 2013 Nov;38(12):2446-55. doi: 10.1038/npp.2013.146. Epub 2013 Jun 10.

6.

NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice.

Moriya R, Shirakura T, Hirose H, Kanno T, Suzuki J, Kanatani A.

Peptides. 2010 Apr;31(4):671-5. doi: 10.1016/j.peptides.2009.11.005. Epub 2009 Nov 17.

PMID:
19925840
7.

Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice.

Moriya R, Mashiko S, Ishihara A, Takahashi T, Murai T, Ito J, Mitobe Y, Oda Z, Iwaasa H, Takehiro F, Kanatani A.

Peptides. 2009 Jul;30(7):1318-22. doi: 10.1016/j.peptides.2009.04.006. Epub 2009 Apr 23.

PMID:
19394383
8.

Endogenous neuropeptide Y depresses the afferent signaling of gastric acid challenge to the mouse brainstem via neuropeptide Y type Y2 and Y4 receptors.

Wultsch T, Painsipp E, Thoeringer CK, Herzog H, Sperk G, Holzer P.

Neuroscience. 2005;136(4):1097-107. Epub 2005 Oct 10.

9.
11.

Gut hormone PYY(3-36) physiologically inhibits food intake.

Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR.

Nature. 2002 Aug 8;418(6898):650-4.

PMID:
12167864
12.

Neuropeptide Y inhibits estrous behavior and stimulates feeding via separate receptors in Syrian hamsters.

Corp ES, Gréco B, Powers JB, Marín Bivens CL, Wade GN.

Am J Physiol Regul Integr Comp Physiol. 2001 Apr;280(4):R1061-8.

13.
14.

Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.

Rastogi SK, Rastogi RB, Singhal RL, Lapierre YD.

Prog Neuropsychopharmacol Biol Psychiatry. 1983;7(2-3):153-64.

PMID:
6137027
15.

Phenotype of striatal cells expressing c-Fos following amphetamine treatment of rats with intrastriatal dopaminergic grafts.

Abrous DN, Bernard V, Le Moal M, Bloch B, Herman JP.

Eur J Neurosci. 1996 Dec;8(12):2521-9.

PMID:
8996801
16.

Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats.

Nadkarni PP, Costanzo RM, Sakagami M.

Diabetes Obes Metab. 2011 May;13(5):408-17. doi: 10.1111/j.1463-1326.2011.01363.x. Epub 2011 Jan 12.

PMID:
21226821
17.

A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents.

Ortiz AA, Milardo LF, DeCarr LB, Buckholz TM, Mays MR, Claus TH, Livingston JN, Mahle CD, Lumb KJ.

J Pharmacol Exp Ther. 2007 Nov;323(2):692-700. Epub 2007 Aug 1.

18.

Apomorphine-induced behavioural sensitization in rats: individual differences, role of dopamine and NMDA receptors.

Võikar V, Soosaar A, Volke V, Kõks S, Bourin M, Männistö PT, Vasar E.

Eur Neuropsychopharmacol. 1999 Dec;9(6):507-14.

PMID:
10625119
19.

The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats.

Koda S, Date Y, Murakami N, Shimbara T, Hanada T, Toshinai K, Niijima A, Furuya M, Inomata N, Osuye K, Nakazato M.

Endocrinology. 2005 May;146(5):2369-75. Epub 2005 Feb 17.

PMID:
15718279

Supplemental Content

Support Center